OUR SERVICES
Discover our range of expert services and solutions for academic and industrial drug discovery programs.
G2L VALIDATE
Cutting-edge chemoproteomics data analysis technologies that enable the discovery of novel binding sites and new therapeutic targets and further support development of drugs.
Leverage the power of G2L Validate platform to analyze chemoproteomics data for highly ligandable sites and high quality therapeutic targets. This platform identifies true ligandable hits with high accuracy, performs site and target tractability analysis, filters out false positives, and provides feedback about off-targets in a reside-agnostic manner. The platform provides target prioritization services via high-value insight on the novelty, tractability and overall value of each chemoproteomics site. The platform can evaluate potential polypharmacological effect of a candidate molecules and provide feedback on multi-targeted assets through consulting services.
G2L DISCOVER
G2L Discover platform is an AI-based identifier of novel ligandable hotspots, including cryptic sites and dynamic pockets on a target protein. This platform is specialized in the assessment of each binding site for covalent reactivity and covalent drug intervention of the dark proteome through a top-down “virtual” chemoproteomics approach.
Virtual Drug Screening
Screen billions of molecules against macromolecular target of interest to identify lead compound(s). Our virtual screening platforms account for molecular flexibility to scan for transitory binding interactions and novel targeting opportunities.